PET/CT in Psoriatic Arthritis

Sponsor
University of Pennsylvania (Other)
Overall Status
Completed
CT.gov ID
NCT01654198
Collaborator
(none)
12
1
75
0.2

Study Details

Study Description

Brief Summary

When patients with psoriasis develop joint pain, it is often hard to decide whether or not the pain is due to psoriatic arthritis (PsA). At this time, doctors use information from the history and physical exam to determine the diagnosis. X-rays, magnetic resonance imaging (MRI) and ultrasound have been used to help with the diagnosis but all three have limitations. A newer imaging technique, whole body Positron Emission Tomography/Computed Tomography (PET/CT) uses the idea that inflammatory cells take up sugar to locate inflammation in the body. Because patients with PsA have inflammatory cells in their joints and tendons, this type of scan allows the physician to take a picture of the whole body and locate inflammation. The investigators have found that some patients with psoriasis (but without arthritis) have inflammation in joints and tendons even before the patient has symptoms. In this study, the investigators will explore how well PET/CT works for assessing inflammation in patients with PsA. This would be a very exciting tool that could be used to find and treat inflammation before it causes damage or pain.

Condition or Disease Intervention/Treatment Phase
  • Radiation: FDG-PET/CT scan

Study Design

Study Type:
Observational
Actual Enrollment :
12 participants
Observational Model:
Case-Only
Time Perspective:
Cross-Sectional
Official Title:
FDG-PET/CT in the Diagnosis and Monitoring of Psoriatic Arthritis
Actual Study Start Date :
Jul 1, 2012
Actual Primary Completion Date :
Oct 2, 2018
Actual Study Completion Date :
Oct 2, 2018

Arms and Interventions

Arm Intervention/Treatment
Psoriatic arthritis

Radiation: FDG-PET/CT scan
FDG-PET/CT is a type of imaging used currently to look for cancer. We are using it to look at inflammation within the joints.

Outcome Measures

Primary Outcome Measures

  1. Primary outcome is inflammation as measured by SUVmax and metabolic volumetric product in the joints and entheses. [At the discretion of the PI]

Secondary Outcome Measures

  1. Correlation of local inflammation in joints and enthesis with systemic inflammatory markers including IL6 and high sensitivity CRP. [At the discretion of the PI]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age 18-80,

  • active psoriatic arthritis (joint or enthesis inflammation)

Exclusion Criteria:
  • Diabetes,

  • pregnant,

  • no active PsA

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Pennsylvania Division of Rheumatology Philadelphia Pennsylvania United States 19104

Sponsors and Collaborators

  • University of Pennsylvania

Investigators

  • Principal Investigator: Alexis R Ogdie, MD, MSCE, University of Pennsylvania

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Pennsylvania
ClinicalTrials.gov Identifier:
NCT01654198
Other Study ID Numbers:
  • 815253
First Posted:
Jul 31, 2012
Last Update Posted:
Dec 8, 2020
Last Verified:
Dec 1, 2020
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 8, 2020